Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
TG Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TGTX
Nasdaq
8731
https://www.tgtherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for TG Therapeutics Inc
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- Apr 18th, 2024 11:30 am
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
- Apr 18th, 2024 11:00 am
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- Apr 15th, 2024 11:30 am
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent Price Movement Underpinned By Its Weak Fundamentals?
- Mar 19th, 2024 11:10 am
13 Best Biotech Stocks To Buy Under $20
- Mar 13th, 2024 11:07 am
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
- Mar 8th, 2024 12:30 pm
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- Mar 1st, 2024 12:30 pm
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 2:22 pm
Q4 2023 TG Therapeutics Inc Earnings Call
- Feb 29th, 2024 3:24 am
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
- Feb 28th, 2024 9:05 pm
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
- Feb 28th, 2024 1:10 pm
TG Therapeutics Inc (TGTX) Announces Fourth Quarter and Full Year 2023 Financial Results
- Feb 28th, 2024 12:52 pm
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
- Feb 28th, 2024 12:00 pm
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
- Feb 27th, 2024 12:30 pm
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
- Feb 26th, 2024 12:00 pm
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
- Feb 23rd, 2024 12:30 pm
Institutional owners may take dramatic actions as TG Therapeutics, Inc.'s (NASDAQ:TGTX) recent 6.8% drop adds to one-year losses
- Feb 21st, 2024 10:43 am
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
- Feb 20th, 2024 3:00 pm
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- Feb 20th, 2024 12:30 pm
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
- Jan 22nd, 2024 11:30 am
Scroll